H. Lundbeck A / S Denmark

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant reductions in mean monthly migraine days (MMDs) compared with placebo1Patients receiving eptinezumab were four times more likely to achieve a reduction of ?75% in MMDs within the first 4 weeks, compared to placebo1The SUNRISE trial met all key secondary efficacy endpoints with improvements seen as early as day 1 and sustained through week 121   

+45 29 82 21 82

+45 30 83 45 01

Palle Holm Olesen

Vice President, Investor Relations

PALO@lundbeck.com

+45 30 83 24 26

About H. Lundbeck A/S

Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.

Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.

As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.

We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.

Lundbeck has approximately 5,700 employees in more than 50 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.
 

References:

Yu S, ePresentation at EAN Congress 2025H. Lundbeck A/S. Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (Sunrise). Clinicaltrials.gov: NCT04921384Steiner TJ, Stovner LJ, Vos T. et al. J Headache Pain 2018; 19: 17.Leonardi M, Steiner TJ, Scher AT, Lipton RB. J Headache Pain. 2005; 6(6): 429– 440.Takeshima, T, et al. J Headache Pain 2019; 20, 111Guidelines for the diagnosis and treatment of migraine in China (2022 edition). Chinese Journal of Pain Medicine 2022, 28 (12) Ashina M, et al. Cephalalgia. 2020 Mar;40(3):241-254.Lipton RB, et al. Neurology. 2020 Mar 31;94(13):e1365-e1377.   
             

CONTACT:

H. Lundbeck A/S
Ottiliavej 9, 2500 Valby, Denmark
+45 3630 1311
info@lundbeck.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/h--lundbeck-a-s/r/new-data-from-phase-iii-trial-confirms-efficacy-of-vyepti---eptinezumab--in-asian-population-with-ch,c4166989

The following files are available for download:

https://mb.cision.com/Main/18215/4166989/3515989.pdf

EAN 2025 Press Release SUNRISE_Final

View original content:https://www.prnewswire.co.uk/news-releases/new-data-from-phase-iii-trial-confirms-efficacy-of-vyepti-eptinezumab-in-asian-population-with-chronic-migraine-302487650.html